Eribulin in advanced liposarcoma and leiomyosarcoma

References

• Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013.
   Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423.
   PubMed Web of Science ®Google Scholar
• Noujaim J, Thway K, Sheri A, et al. Histology-driven therapy: the importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. Int J Surg Pathol. 2016 Feb;24(1):5–15.
   PubMed Web of Science ®Google Scholar
• Buesa JM, Mouridsen HT, van Osterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991;2:307–309.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38:543–549.
   PubMed Web of Science ®Google Scholar
• Bai RL, Paull KD, Herald CL, et al. Halichondrin B and Homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991;266:15882–15889.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft -tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12:1045–1052.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629–1637.
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–923.
   PubMed Web of Science ®Google Scholar
• Thara E, Gitlitz BJ. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy. Future Oncol. 2014;10(12):1913–1924.
   PubMed Web of Science ®Google Scholar
• Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70:1866–1875.
   PubMed Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013–1021.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–1095.
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64:5760–5766.
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Okamoto K, Adachi Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105:1334–1342.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110:1497–1505.
   PubMed Web of Science ®Google Scholar
• Yang J, Xiaoling D, Wang G, et al. Mesenchymal to epithelial transition in sarcomas. Eur J Canc. 2014;50:593–601.
   PubMed Web of Science ®Google Scholar
• Kawano S, Asano M, Adachi Y, et al. Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma. Anticancer Res. 2016;36:1553–1562.
   PubMed Web of Science ®Google Scholar
• Agoulnik SI, Kawano S, Taylor N, et al. Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. Vasc Cell. 2014;6. DOI:10.1186/2045-824X-6-3.
   PubMedGoogle Scholar
• Ueda S, Saeki T, Takeuchi H, et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer. 2016 May 24;114:1212–1218.
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Reynolds CP, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60:1325–1332.
   PubMed Web of Science ®Google Scholar
• Kurebayashi J, Kanomata N, Yamashita T, et al. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells. Breast Cancer. 2016 May;23(3):425–436. Epub 2015 Jan 1.
   PubMed Web of Science ®Google Scholar
• Luyimbazi D, Luu TH, Xing Q, et al. Effect of eribulin on cell growth and PI3K pathway activity with and without RAD001 in triple-negative and HER2-expressing breast cancer. J Clin Oncol. 2013;173(26_suppl):31.
   Google Scholar
• Kuznetsov G, Tendyke K, Yu M, et al. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics –– Oct 22–26, 2007; San Francisco, CA. Mol Cancer Ther. 2007;6(11 Suppl): Abstract 58.
   Google Scholar
• LaPointe NE, Morfini G, Brady ST, et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–239.
   PubMed Web of Science ®Google Scholar
• Morgan RJ, Synold TW, Longmate JA, et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov;76(5):897–907.
   PubMed Web of Science ®Google Scholar
• Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009;15(12):4207–4212.
   PubMed Web of Science ®Google Scholar
• Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4213–4219.
   PubMed Web of Science ®Google Scholar
• Mukohara T, Nagai S, Mukai H, et al. Eribulin mesylate in patients with refractory cancers: a phase I study. Invest New Drugs. 2012 Oct;30(5):1926–1933.
   PubMed Web of Science ®Google Scholar
• Synold TW, Lawrence J, Xi B, et al. Human pharmacokinetics of E7389 (Halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC). Proc Amsoc Clin Oncol. 2003;22. [abstr575]. p. 144.
   Google Scholar
• Minami H, Mukohara T, Nagai S, et al. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer Suppl. 2008;6:140. [abst 446].
   Web of Science ®Google Scholar
• Devriese LA, Witteven PO, Marchetti S, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharm. 2012;70:823–832.
   PubMed Web of Science ®Google Scholar
• Tan AR, Sarantopoulos J, Lee J, et al. Pharmacokinetics (PK) of eribulin mesylate in cancer patients (Pts) with normal and impaired renal function. Cancer Chemother Pharmacol 2015 76:1051-1061. doi:10.1007/s00280-015-2878-5.
   Google Scholar
• Devriese LA, Mergui-Roelvink M, Wanders J, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs. 2013;31:381–389.
   PubMed Web of Science ®Google Scholar
• Kawai A, Araki N, Naito Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2016 Dec 1;1–8. DOI:10.1093/jjco/hyw175.
   Web of Science ®Google Scholar
• Demetri GD, Schöffski P, Grignani G, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. J Clin Oncol. [Forthcoming].
   Google Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [published correction in J Clin Oncol. 2007;25(24):3790]. J Clin Oncol. 2007;25(19):2755–2763.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17(9):1213–1220.
   PubMed Web of Science ®Google Scholar
• Seddon B, Whelan J, Leahy M, et al. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcoma (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(suppl; abstr 10500).
   Google Scholar
• Garcia-del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29:2528–2533.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786–793.
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595–602.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27:3126–3132.
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886.
   PubMed Web of Science ®Google Scholar
• Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488–489.
   PubMed Web of Science ®Google Scholar
• Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–2861.
   PubMed Web of Science ®Google Scholar
• Singer S, Socci ND, Ambrosini G, et al. gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67:6626–6636.
   PubMed Web of Science ®Google Scholar